Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

.

Other Chaperone Programs:

Amicus is accelerating its investment in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease, funded in part by a grant from the Michael J. Fox Foundation. In addition to the work in Parkinson's, Amicus is investing in new research aimed at evaluating disease targets for other neurodegenerative disorders and metabolic disorders.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire also reimburses worldwide development costs on a 50/50 basis. Under the agreement, Shire received rights to commercialize these products outside of the United States. Amicus retains all rights to commercialize these products in the United States. Amicus will lead development operations through the end of Phase 2 clinical trials. The companies will then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-US regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended March 31, 2008, was $7.7 million as compared to $9.7 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended March 31, 2008, was $6.4 million as compared to $8.9 million and the same period in 2007.

Amic
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... /PRNewswire/ - bioLytical Laboratories Inc., a leader in rapid ... Sensitivity of a rapid point of care assay for ... for HIV gp41 IgM antibodies " has been published ... INSTI,s ability to detect early HIV infection.  ... th annual International AIDS Society Conference, which highlighted ...
(Date:9/3/2015)... ... 2015 , ... Michigan-based technology startup Halo Wearables ... The device, called the Halo H1, is a wearable that monitors the user’s ... track trending interstitial fluid levels in the body, in addition to sodium-potassium ratios ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... systems, analytical testing, education and consulting services for the medical device sector, ... products/processes development, design control, validation, quality assurance and regulatory compliance. Avarent will ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
Breaking Biology Technology:bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3
... Investigating programmed cell death , Wei-ping Yang ... ,Stratagene , The apoptotic response is a complex ... of genes that interact with and respond to ... ,sets that are specific for genes ...
... pathway activation , Li Xu Tim Sanchez ... Stratagenes PathDetect in vivo signal transduction pathway,reporting systems ... activation of signal,transduction pathways. To expand the utility ... and pFA-Elk1 plasmids with new, improved fusion,trans-activator plasmids. ...
... with TKB1 competent cells , David ... for Molecular Biology and Biotechnology, McMaster University,Ontario, ... bacteria are used to affinity purify,cellular proteins, ... on,the ErbB2/Neu receptor tyrosine kinase (RTK). This ...
Cached Biology Technology:RT-PCR Primers for the Study of Apoptosis 2RT-PCR Primers for the Study of Apoptosis 3RT-PCR Primers for the Study of Apoptosis 4RT-PCR Primers for the Study of Apoptosis 5RT-PCR Primers for the Study of Apoptosis 6RT-PCR Primers for the Study of Apoptosis 7Improved Vectors for PathDetect Trans-Reporting Systems 2Improved Vectors for PathDetect Trans-Reporting Systems 3Improved Vectors for PathDetect Trans-Reporting Systems 4Improved Vectors for PathDetect Trans-Reporting Systems 5TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 2TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 3TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 4TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 5
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... ITHACA, N.Y. - A new study of maize has ... the genome. New techniques may allow breeders and researchers to ... new varieties that were not easily possible before. Publishing ... researchers, whose senior and first author are at Cornell, have ...
... COLLEGE PARK, Md.-John Fisher, associate professor in the Fischell ... the 2009 Bioscience Research and Technology Review Day with ... other types of tissue for implantation. Fisher,s technology ... minute pitch by faculty members and graduate students at ...
... the first time, scientists have successfully used a method called ... for a mendelian disorder. Mendelian disorders, such as ... one or more mutations in a single gene, typically a ... code for proteins taken together are called the exome. The ...
Cached Biology News:New map of variation in maize genetics holds promise for developing new varieties 2Bioreactor for bone tissue engineering wins professor venture fair 2Bioreactor for bone tissue engineering wins professor venture fair 3Causative gene of a rare disorder discovered by sequencing only protein-coding regions of genome 2Causative gene of a rare disorder discovered by sequencing only protein-coding regions of genome 3
... For the professional, student, or faculty researcher, the ... accelerate your research and improve the quality of ... is the edge that researchers using LI-COR DNA ... years. The 4300 System is a third generation ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... at various temperatures, this chamber provides ... clean heating unit to maintain a ... Transparent panels allow full visibility, and ... to the work area. Includes a ...
Biology Products: